Abstract

The primary objective of this proposal is to continue the strong participation of the USC ACTU in developmental therapeutics in HIV positive persons in priority areas: primary infection; opportunistic infections; oncology; and neurologic complications. The USC ACTU was one of the original 13 ACTUs with inception in 1986. Through July 2, 1991 the USC ACTU had accrued 872 patients to various ACTU protocols. In the current proposal, it is planned to accrue a total of 150 new patients per year distributed among the four priority areas mentioned above. To achieve this overall goal, USC has applied for several of the components listed in the RFA. The work subsumed under Part A, Adult Clinical Trials Unit, will cover the recruitment, clinical evaluation, and follow up of patients as well as the required immunologic tests. USC has a strong and experienced retrovirology laboratory, very well coordinated and integrated with the clinical ACTU. Therefore, proposals under Part C, C.1, protocol mandated virology, and under Part C, C.3, developmental virologic research, have been submitted. The USC faculty has a major interest in clinical pharmacology. Therefore proposals have been submitted under part C.2 of the RFA to conduct protocol mandated pharmacology laboratory tests.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI027673-07
Application #
3547465
Study Section
Special Emphasis Panel (SRC (35))
Project Start
1992-03-01
Project End
1995-02-28
Budget Start
1993-01-01
Budget End
1993-12-31
Support Year
7
Fiscal Year
1993
Total Cost
Indirect Cost

  Institution

Name
University of Southern California
Department
Type
Schools of Medicine
DUNS #
041544081
City
Los Angeles
State
CA
Country
United States
Zip Code
90089

  Publications

Sattler, Fred R; Chelliah, Daniel; Wu, Xingye et al. (2018) Biomarkers Associated with Death After Initiating Treatment for Tuberculosis and HIV in Patients with Very Low CD4 Cells. Pathog Immun 3:46-62
Hulgan, Todd; Stein, James H; Cotter, Bruno R et al. (2013) Mitochondrial DNA variation and changes in adiponectin and endothelial function in HIV-infected adults after antiretroviral therapy initiation. AIDS Res Hum Retroviruses 29:1293-9
Wohl, David A; Kendall, Michelle A; Feinberg, Judith et al. (2013) The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit. PLoS One 8:e78676
Bronke, Corine; Almeida, Coral-Ann M; McKinnon, Elizabeth et al. (2013) HIV escape mutations occur preferentially at HLA-binding sites of CD8 T-cell epitopes. AIDS 27:899-905
Huang, Jeannie S; Hughes, Michael D; Riddler, Sharon A et al. (2013) Bone mineral density effects of randomized regimen and nucleoside reverse transcriptase inhibitor selection from ACTG A5142. HIV Clin Trials 14:224-34
Carlson, Jonathan M; Brumme, Chanson J; Martin, Eric et al. (2012) Correlates of protective cellular immunity revealed by analysis of population-level immune escape pathways in HIV-1. J Virol 86:13202-16
Kang, M; Cu-Uvin, S (2012) Association of HIV viral load and CD4 cell count with human papillomavirus detection and clearance in HIV-infected women initiating highly active antiretroviral therapy. HIV Med 13:372-8
Haubrich, Richard H; Riddler, Sharon A; Ribaudo, Heather et al. (2011) Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection AIDS 25:2269-78
Hulgan, Todd; Haubrich, Richard; Riddler, Sharon A et al. (2011) European mitochondrial DNA haplogroups and metabolic changes during antiretroviral therapy in AIDS Clinical Trials Group Study A5142. AIDS 25:37-47
Almeida, Coral-Ann M; Bronke, Corine; Roberts, Steven G et al. (2011) Translation of HLA-HIV associations to the cellular level: HIV adapts to inflate CD8 T cell responses against Nef and HLA-adapted variant epitopes. J Immunol 187:2502-13

Showing the most recent 10 out of 55 publications